Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression - PubMed (original) (raw)
. 2006 Jun 8;25(24):3408-23.
doi: 10.1038/sj.onc.1208964. Epub 2005 Sep 26.
Affiliations
- PMID: 16186809
- DOI: 10.1038/sj.onc.1208964
Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression
R S Muraoka-Cook et al. Oncogene. 2006.
Abstract
We have examined the effects of transforming growth factor-beta (TGFbeta) signaling on mammary epithelial cell survival. Transgenic mice expressing an active mutant of Alk5 in the mammary gland (MMTV-Alk5(T204D)) exhibited reduced apoptosis in terminal endbuds and during postlactational involution. Transgene-expressing mammary cells contained lower Smad2/3 and higher c-myc levels than controls, high ligand-independent phosphatidylinositol-3 kinase (PI3K) and Akt activities, and were insensitive to TGFbeta-mediated growth arrest. Treatment with a proteasome inhibitor increased Smad2/3 levels and ligand-independent Smad transcriptional reporter activity, as well as reduced both c-myc protein and basal cell proliferation. Treatment with an Alk5 kinase small-molecule inhibitor upregulated Smad2/3 levels, reduced PI3K activity, P-Akt, and c-myc, and inhibited cell survival. Although Alk5(T204D)-expressing mice did not develop mammary tumors, bigenic MMTV-Alk(T204D) x Neu mice developed cancers that were more metastatic than those occurring in MMTV-Neu transgenics. These data suggest that (1) TGFbeta can signal to PI3K/Akt and enhance mammary epithelial cell survival in vivo before cytological or histological evidence of transformation, and (2) TGFbeta signaling can provide epithelial cells with a 'gain-of-function' effect that synergizes with oncogene-induced transformation.
Similar articles
- Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F, Ungefroren H. Schniewind B, et al. Oncogene. 2007 Jul 19;26(33):4850-62. doi: 10.1038/sj.onc.1210272. Epub 2007 Feb 12. Oncogene. 2007. PMID: 17297450 - A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE. Suzuki E, et al. Cancer Res. 2007 Mar 1;67(5):2351-9. doi: 10.1158/0008-5472.CAN-06-2389. Cancer Res. 2007. PMID: 17332368 - p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P. Cabodi S, et al. Cancer Res. 2006 May 1;66(9):4672-80. doi: 10.1158/0008-5472.CAN-05-2909. Cancer Res. 2006. PMID: 16651418 - Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression.
Muraoka-Cook RS, Dumont N, Arteaga CL. Muraoka-Cook RS, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):937s-43s. Clin Cancer Res. 2005. PMID: 15701890 Review. - Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5).
Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM. Singh J, et al. Curr Opin Drug Discov Devel. 2004 Jul;7(4):437-45. Curr Opin Drug Discov Devel. 2004. PMID: 15338953 Review.
Cited by
- HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression.
Shi Q, Huang F, Wang Y, Liu H, Deng H, Chen YG. Shi Q, et al. J Cell Biol. 2024 Apr 1;223(4):e202307138. doi: 10.1083/jcb.202307138. Epub 2024 Feb 26. J Cell Biol. 2024. PMID: 38407425 Free PMC article. - Epithelial-mesenchymal transition in cancer stem cells: Therapeutic implications.
Varun BR, Ramani P, Arya I, Palani J, Joseph AP. Varun BR, et al. J Oral Maxillofac Pathol. 2023 Apr-Jun;27(2):359-363. doi: 10.4103/jomfp.jomfp_308_22. Epub 2023 Jul 13. J Oral Maxillofac Pathol. 2023. PMID: 37854925 Free PMC article. Review. - A narrative review of the relationship between TGF-β signaling and gynecological malignant tumor.
Luo F, Huang Y, Li Y, Zhao X, Xie Y, Zhang Q, Mei J, Liu X. Luo F, et al. Ann Transl Med. 2021 Oct;9(20):1601. doi: 10.21037/atm-21-4879. Ann Transl Med. 2021. PMID: 34790807 Free PMC article. Review. - The Toxic Impact of Honey Adulteration: A Review.
Fakhlaei R, Selamat J, Khatib A, Razis AFA, Sukor R, Ahmad S, Babadi AA. Fakhlaei R, et al. Foods. 2020 Oct 26;9(11):1538. doi: 10.3390/foods9111538. Foods. 2020. PMID: 33114468 Free PMC article. Review. - Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.
Dai Y, Wu Z, Lang C, Zhang X, He S, Yang Q, Guo W, Lai Y, Du H, Peng X, Ren D. Dai Y, et al. Theranostics. 2019 Aug 14;9(21):6063-6079. doi: 10.7150/thno.36735. eCollection 2019. Theranostics. 2019. PMID: 31534537 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA68485/CA/NCI NIH HHS/United States
- P50 CA98131/CA/NCI NIH HHS/United States
- R01 AG022413/AG/NIA NIH HHS/United States
- R01 CA80195/CA/NCI NIH HHS/United States
- R01 DK069921/DK/NIDDK NIH HHS/United States
- R010 CA62212/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous